REVIEW SERIES

Lung cancer • 8: Management of malignant mesothelioma

C Parker, E Neville

Respiratory Centre, St Mary’s Hospital, Portsmouth PO3 6AD, Hants, UK

Correspondence to:
Correspondence to:
Dr E Neville, Respiratory Centre, St Mary’s Hospital, Portsmouth PO3 6AD, Hants, UK;
edmund.neville@smail01.porthosp.swest.nhs.uk

---

Malignant mesothelioma is a relatively common malignant tumour which is associated with prior exposure to asbestos. The diagnosis, histology, prognosis, and management of this disease are reviewed. The disappointing outcome of most curative treatment strategies is discussed and improved palliation is highlighted.

---

Keywords: malignant mesothelioma; diagnosis; prognosis; treatment

The first 150 words of the full text of this article appear below.

Malignant mesothelioma is a challenging disease that understandably causes considerable distress and anxiety to patients, relatives, and clinicians. The incidence of mesothelioma has been steadily increasing over the past 30 years, and is expected to continue until 2020 with a projected 1300 cases each year. The 1940s male birth cohort is particularly affected, mesothelioma accounting for approximately 1% of all deaths.^1–3 The incidence increases with age and is approximately 10 times higher in men aged 60–64 years than in those aged 30–34.

There is an association with the inhalation of asbestos fibres, which frequently has occurred years previously and sometimes in a seemingly low dose. Mesothelioma is rare in patients without any direct occupational exposure or indirect paraoccupational or environmental exposure.⁴ Current estimates suggest an occupational history is obtained in over 90% of patients.⁵ There is no evidence to suggest a safe or threshold level of exposure, but the risk . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Kothmaier, H, Quehenberger, F, Halbwedl, I, Morbini, P, Demirag, F, Zeren, H, Comin, C E, Murer, B, Cagle, P T, Attanoos, R, Gibbs, A R, Galateau-Salle, F, Popper, H H (2008). EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors. Thorax 63: 345-351 [Abstract] [Full Text]  
• Bottomley, A., Coens, C., Efficace, F., Gaafar, R., Manegold, C., Burgers, S., Vincent, M., Legrand, C., van Meerbeeck, J. P. (2007). Symptoms and Patient-Reported Well-Being: Do They Predict Survival in Malignant Pleural Mesothelioma? A Prognostic Factor Analysis of EORTC-NCIC 08983: Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma. JCO 25: 5770-5776 [Abstract] [Full Text]  
• Bottomley, A., Gaafa, R., Manegold, C., Burgers, S., Coens, C., Legrand, C., Vincent, M., Giaccone, G., Van Meerbeeck, J. (2006). Short-Term Treatment-Related Symptoms and Quality of Life: Results From an International Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. JCO 24: 1435-1442 [Abstract] [Full Text]  
• Wedzicha, J A, Johnston, S L, Mitchell, D M (2003). Annual report October 2002 to September 2003. Thorax 58: 1015-1017 [Full Text]